Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Quintiles has entered into a collaboration agreement to promote Almirall's new long-acting antimuscarinic (LAMA) delivered via a multi-dose inhaler for the treatment of chronic obstructive pulmonary disease (COPD).
Subscribe to our email newsletter
Following a positive opinion of Almirall’s new LAMA as a maintenance bronchodilator by the Committee for Medicinal Products for Human Use of the European Medicines Agency (CHMP) on 28 May 2012, the European Commission finally approved the medicine on 24 July 2012.
Almirall general manager Carlos Gallardo said, "Our long-term alignment with Quintiles will help us to ensure that new therapeutic options are made available for COPD patients throughout the UK."
Quintiles UK commercial solutions managing director Robert Taylor said the partnership allows the company’s engaged workforce to drive success across the life cycle of Almirall’s respiratory products.
"The FDA also issued final positive feedback on Almirall’s first product in COPD on July 24," Taylor added.